Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.

Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P.

Int J Cancer. 2019 Jul 22. doi: 10.1002/ijc.32583. [Epub ahead of print]

PMID:
31330065
2.

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.

Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, Barba M, Maugeri-Saccà M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Della Giulia M, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T.

Oncotarget. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22.

3.

Metformin and breast cancer: basic knowledge in clinical context.

Pizzuti L, Vici P, Di Lauro L, Sergi D, Della Giulia M, Marchetti P, Maugeri-Saccà M, Giordano A, Barba M.

Cancer Treat Rev. 2015 May;41(5):441-7. doi: 10.1016/j.ctrv.2015.03.002. Epub 2015 Mar 17. Review.

PMID:
25816698
4.

Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial.

Pace A, Giannarelli D, Galiè E, Savarese A, Carpano S, Della Giulia M, Pozzi A, Silvani A, Gaviani P, Scaioli V, Jandolo B, Bove L, Cognetti F.

Neurology. 2010 Mar 2;74(9):762-6. doi: 10.1212/WNL.0b013e3181d5279e.

PMID:
20194916
5.

[Treatment of malignant pleural effusion by pleurodesis with talc].

Filippetti M, Crucitti G, Vanni B, Della Giulia M, Foggi P, Del Monte G.

Chir Ital. 2000 Sep-Oct;52(5):541-7. Italian.

PMID:
11190547
6.

A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial.

Rinaldi M, Crinò L, Scagliotti GV, Mosconi AM, De Marinis F, Gridelli C, Selvaggi G, Della Giulia M, Darwish S, Porrozzi S, Novello S, Cipri A, Bartolucci R, Calandri C, Tonato M.

Ann Oncol. 2000 Oct;11(10):1295-300.

PMID:
11106119
7.

Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial.

Crinò L, Mosconi AM, Scagliotti G, Selvaggi G, Novello S, Rinaldi M, Della Giulia M, Gridelli C, Rossi A, Calandri C, De Marinis F, Noseda M, Tonato M.

J Clin Oncol. 1999 Jul;17(7):2081-5.

PMID:
10561261
8.

[IX. International Congress on cancer treatment. 2-5 February 1999, Paris, France].

Della Giulia M.

Clin Ter. 1999 Mar-Apr;150(2):99-101. Italian. No abstract available.

PMID:
10396857
9.

Single-agent ifosfamide in the treatment of anthracycline-refractory adult sarcomas.

Lopez M, Carpano S, Amodio A, Gionfra T, Della Giulia M, Foggi P, Manfredi C, Del Monte G.

Clin Ter. 1998 Sep-Oct;149(5):331-3.

PMID:
10052244
10.

[Simultaneous infusion of vinorelbin and taxol as first-line chemotherapy in metastasized breast cancer].

Vici P, Conti F, Amodio A, Belli F, Della Giulia M, Mariotti S, Gionfra T, Lopez M.

Clin Ter. 1998 Jul-Aug;149(4):255-9. Italian.

PMID:
9866885
11.

Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial.

Crinò L, Mosconi AM, Scagliotti GV, Selvaggi G, Rinaldi M, Della Giulia M, Gridelli C, Calandri C, De Marinis F, Noseda M, Tonato M.

Semin Oncol. 1998 Aug;25(4 Suppl 9):23-6.

PMID:
9728581
12.

Triple combination antimicrobial regimen in the treatment of infections of neutropenic cancer patients.

Casali A, Santini S, Della Giulia M, Di Lauro L, Vici P, Gionfra T, Sega FM.

J Exp Clin Cancer Res. 1997 Sep;16(3):321-4.

PMID:
9387908
13.

A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer.

Nardi M, Della Giulia M, Pollera CF, Marolla P, Ruggeri EM, Iacovelli A, Atlante G, Calabresi F.

Cancer Chemother Pharmacol. 1996;38(3):298-301.

PMID:
8646807
14.

Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a.

Garaci E, Lopez M, Bonsignore G, Della Giulia M, D'Aprile M, Favalli C, Rasi G, Santini S, Capomolla E, Vici P, et al.

Eur J Cancer. 1995 Dec;31A(13-14):2403-5.

PMID:
8652276
15.

Neurophysiological examination of end-plate function in patients with lung cancer.

Jandolo B, Della Giulia M, Pace A, Pietrangeli A, Bove L, Innocenti P, Lopez M.

Electromyogr Clin Neurophysiol. 1995 Jun-Jul;35(4):247-50.

PMID:
7555930

Supplemental Content

Loading ...
Support Center